Andrew Cheng - 08 Dec 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President and CEO, Director
Signature
Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
08 Dec 2021
Net transactions value
$0
Form type
4
Filing time
10 Dec 2021, 16:15:52 UTC
Previous filing
03 Dec 2021
Next filing
04 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 +261,662 $0.000000 261,662 08 Dec 2021 Common Stock 261,662 $21.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in 48 equal monthly installments commencing on December 8, 2021.